Canadian Scientists May Wipe out HIV

Wednesday, December 21, 2011


Canadian researchers working on a vaccine to prevent HIV announced Tuesday they have received approval from the U.S. Food and Drug Administration to begin clinical trials on humans in January.

A team led by Dr. Chil-Yong Kang, a virologist at the University of Western Ontario in London, Ont., plans to start Phase 1 of clinical trials on 40 HIV-positive patients to test the safety of the vaccine.




“FDA approval for human clinical trials is an extremely significant milestone for our vaccine, which has the potential to save the lives of millions of people around the world by preventing HIV infection," says Kang, a researcher and professor at Western's Schulich School of Medicine & Dentistry.

Western President Amit Chakma says, "This joint venture between Sumagen and Western is a prime example of what collaboration between private industry and university researchers can achieve. Dr. Kang and his team are to be commended for their exceptional talent and remarkable persistence in developing a vaccine that addresses a tragic health crisis affecting millions of people around the globe."


Montreal Gazette